Laurus Labs Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹377.75
- Today's High:
- ₹405.45
- Open Price:
- ₹405
- 52W Low:
- ₹278.6462
- 52W High:
- ₹567.7985
- Prev. Close:
- ₹406.85
- Volume:
- 163301
Company Statistics
- Market Cap.:
- ₹217.35 billion
- Book Value:
- 74.956
- Revenue TTM:
- ₹56.83 billion
- Operating Margin TTM:
- 17.41%
- Gross Profit TTM:
- ₹32.72 billion
- Profit Margin:
- 9.92%
- Return on Assets TTM:
- 11.06%
- Return on Equity TTM:
- 21.42%
Company Profile
Laurus Labs Limited had its IPO on under the ticker symbol LAURUSLABS.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Laurus Labs Limited has a staff strength of 5,753 employees.
Stock update
Shares of Laurus Labs Limited opened at ₹405 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹377.75 - ₹405.45, and closed at ₹384.25.
This is a -5.55% slip from the previous day's closing price.
A total volume of 163,301 shares were traded at the close of the day’s session.
In the last one week, shares of Laurus Labs Limited have slipped by -2.61%.
Laurus Labs Limited's Key Ratios
Laurus Labs Limited has a market cap of ₹217.35 billion, indicating a price to book ratio of 5.6627 and a price to sales ratio of 3.8721.
In the last 12-months Laurus Labs Limited’s revenue was ₹56.83 billion with a gross profit of ₹32.72 billion and an EBITDA of ₹13.18 billion. The EBITDA ratio measures Laurus Labs Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Laurus Labs Limited’s operating margin was 17.41% while its return on assets stood at 11.06% with a return of equity of 21.42%.
In Q2, Laurus Labs Limited’s quarterly earnings growth was a negative -90.1% while revenue growth was a negative 23.2%.
Laurus Labs Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 38.6124
- PEG
Its diluted EPS in the last 12-months stands at ₹10.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Laurus Labs Limited’s profitability.
Laurus Labs Limited stock is trading at a EV to sales ratio of 4.2289 and a EV to EBITDA ratio of 14.8919. Its price to sales ratio in the trailing 12-months stood at 3.8721.
Laurus Labs Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 19.15%.
Balance sheet and cash flow metrics
- Total Assets
- ₹76.60 billion
- Total Liabilities
- ₹24.32 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 19.15%
Laurus Labs Limited ended 2024 with ₹76.60 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹76.60 billion while shareholder equity stood at ₹40.38 billion.
Laurus Labs Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹24.32 billion in other current liabilities, 1077300000.00 in common stock, ₹39.30 billion in retained earnings and ₹2.46 billion in goodwill. Its cash balance stood at ₹456.70 million and cash and short-term investments were ₹647.70 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹7.61 billion.
Laurus Labs Limited’s total current assets stands at ₹34.62 billion while long-term investments were ₹0 and short-term investments were ₹163.10 million. Its net receivables were ₹15.80 billion compared to accounts payable of ₹7.11 billion and inventory worth ₹16.85 billion.
In 2024, Laurus Labs Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Laurus Labs Limited paid ₹0.19 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹384.25
- 52-Week High
- ₹567.7985
- 52-Week Low
- ₹278.6462
- Analyst Target Price
- ₹
Laurus Labs Limited stock is currently trading at ₹384.25 per share. It touched a 52-week high of ₹567.7985 and a 52-week low of ₹567.7985. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹376.54 and 200-day moving average was ₹351.45 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3583% of the company’s stock are held by insiders while 2411.8% are held by institutions.
Frequently Asked Questions About Laurus Labs Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.